Edition:
India

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

54.62USD
4 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$54.62
Open
$53.45
Day's High
$54.93
Day's Low
$52.30
Volume
107,237
Avg. Vol
246,343
52-wk High
$63.44
52-wk Low
$8.51

Latest Key Developments (Source: Significant Developments)

Arcturus Therapeutics Announces Proposed Public Offering Of Common Stock
Wednesday, 29 Jul 2020 

July 28 (Reuters) - Arcturus Therapeutics Holdings Inc ::ARCTURUS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ARCTURUS THERAPEUTICS HOLDINGS - INTENDS TO USE NET PROCEEDS OF OFFERING TO DEVELOP, TEST & MANUFACTURE CO'S LUNAR-COV19 VACCINE CANDIDATE.  Full Article

Arcturus, Duke-Nus Say Singapore Approves Clinical Trials For COVID-19 Vaccine Candidate
Wednesday, 22 Jul 2020 

July 22 (Reuters) - Arcturus Therapeutics , Duke-NUS::SAY CLINICAL TRIALS FOR COVID-19 VACCINE CANDIDATE HAS BEEN APPROVED TO PROCEED BY SINGAPORE REGULATOR.SAY WILL INITIATE HUMAN DOSING OF VACCINE CANDIDATE AS SOON AS POSSIBLE.SAY STUDY WILL EVALUATE SEVERAL DOSE LEVELS OF VACCINE CANDIDATE IN UP TO 108 ADULTS, INCLUDING OLDER ADULTS.  Full Article

Arcturus Therapeutics & Duke-Nus Receive Approval To Proceed With Phase 1/2 Clinical Trial For Covid-19 Vaccine Candidate
Tuesday, 21 Jul 2020 

July 21 (Reuters) - Arcturus Therapeutics Holdings Inc ::ARCTURUS THERAPEUTICS & DUKE-NUS RECEIVED APPROVAL TO PROCEED WITH PHASE 1/2 CLINICAL TRIAL FOR COVID-19 VACCINE CANDIDATE, LUNAR-COV19.ARCTURUS THERAPEUTICS HOLDINGS INC - HUMAN DOSING OF LUNAR-COV19 EXPECTED SOON.ARCTURUS THERAPEUTICS - DIFFERENTIATED STARR MRNA VACCINE EXPECTED TO PRODUCE HUMORAL AND CELLULAR IMMUNITY AT VERY LOW DOSES.ARCTURUS THERAPEUTICS - NEW PRECLINICAL DATA DEMONSTRATES NEUTRALIZING ANTIBODY TITERS CONTINUE TO INCREASE FOR 50 DAYS AFTER SINGLE ADMINISTRATION.ARCTURUS THERAPEUTICS HOLDINGS INC - ARCTURUS & DUKE-NUS WILL INITIATE HUMAN DOSING OF LUNAR-COV19 AS SOON AS POSSIBLE.  Full Article

Arcturus Therapeutics Files For Mixed Shelf Of Upto $200 Million
Saturday, 9 May 2020 

May 8 (Reuters) - Arcturus Therapeutics Holdings Inc ::ARCTURUS THERAPEUTICS HOLDINGS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Arcturus Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 16 Apr 2020 

April 15 (Reuters) - Arcturus Therapeutics Holdings Inc ::ARCTURUS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Arcturus Therapeutics Reports Fourth Quarter And Year End 2019 Financial Results
Thursday, 12 Mar 2020 

March 11 (Reuters) - Arcturus Therapeutics Holdings Inc ::ARCTURUS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS.Q4 REVENUE $3.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.6 MILLION.Q4 LOSS PER SHARE $0.76.Q4 EARNINGS PER SHARE ESTIMATE $-0.53 -- REFINITIV IBES DATA.ARCTURUS THERAPEUTICS LTD - CORONAVIRUS VACCINE PROGRAM INITIATED.ARCTURUS THERAPEUTICS LTD - IND FILED FOR FLAGSHIP PROGRAM ARCT-810.ARCTURUS THERAPEUTICS LTD - CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $71.4 MILLION AS OF DECEMBER 31, 2019.ARCTURUS THERAPEUTICS LTD - COMPANY'S CURRENT CASH POSITION IS EXPECTED TO BE SUFFICIENT TO SUPPORT OPERATIONS THROUGH Q1 OF 2021.  Full Article

Arcturus Therapeutics Reports Q3 Loss Per Share Of $0.56
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.IND APPLICATION FOR ARCT-810, A TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY, IS ON TRACK FOR Q1 2020 FILING.AT SEPTEMBER 30, 2019, ARCTURUS HAD CASH AND CASH EQUIVALENTS TOTALING $74.2 MILLION.  Full Article

Arcturus Therapeutics Q2 Loss Per Share $0.07
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.07.Q2 EARNINGS PER SHARE ESTIMATE $-0.64 -- REFINITIV IBES DATA.AT JUNE 30, 2019, CO HAD CASH AND CASH EQUIVALENTS TOTALING $55.8 MILLION.  Full Article

Arcturus Therapeutics Announces Additional Registered Direct Offering Of Common Stock
Friday, 2 Aug 2019 

Aug 2 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES $2.3 MILLION ADDITIONAL REGISTERED DIRECT OFFERING OF COMMON STOCK.AGREEMENT WITH INSTITUTIONAL INVESTOR FOR PURCHASE & SALE IN OFFERING OF 200,000 SHARES OF COMMON STOCK AT $11.50 PER SHARE.INTENDS TO USE PROCEEDS FROM OFFERING TO FUND CONTINUED RESEARCH AND DEVELOPMENT INITIATIVES IN CONNECTION WITH ITS PRODUCT PIPELINE.  Full Article

Arcturus Therapeutics Says Co & Curevac Terminated Co-Development And Co-Commercialization Agreement Dated Jan 1, 2018
Tuesday, 30 Jul 2019 

July 29 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD - ON JULY 26, CO & CUREVAC TERMINATED CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT DATED JAN 1, 2018.ARCTURUS THERAPEUTICS LTD - CUREVAC AGREED TO MAKE A ONE-TIME PAYMENT TO CO OF $4 MILLION IN CONSIDERATION FOR TERMINATION.ARCTURUS THERAPEUTICS SAYS AMENDED DEVELOPMENT AND OPTION AGREEMENT WITH CUREVAC AG - SEC FILING.ARCTURUS THERAPEUTICS LTD - AMENDMENT REDUCES OVERALL NUMBER OF MAXIMUM TARGETS TO BE RESERVED AND LICENSED FROM 15 TO 10 TARGETS.ARCTURUS THERAPEUTICS LTD - AMENDMENT MODIFIES TIME PERIOD DURING WHICH CUREVAC MAY SELECT POTENTIAL TARGETS TO BE LICENSED FROM CO.  Full Article

BRIEF-Arcturus Therapeutics To Be Added To Russell 2000® Index

* ARCTURUS THERAPEUTICS TO BE ADDED TO RUSSELL 2000® INDEX Source text for Eikon: Further company coverage: